Royalty Pharma (RPRX) Total Liabilities (2019 - 2026)

Royalty Pharma has disclosed Total Liabilities across 8 years of filings, most recently posting $10.0 billion for Q2 2026.

• In Q2 2026, Total Liabilities rose 13.76% year-over-year to $10.0 billion; the TTM figure through Jun 2026 stood at $10.0 billion (up 13.76% YoY), while the FY2025 annual figure was $9.9 billion, up 25.7% from the prior year.
• Total Liabilities came in at $10.0 billion for Q2 2026 at Royalty Pharma, up from $9.9 billion in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $10.0 billion in Q2 2026 to a low of $6.3 billion in Q1 2024.
• Average Total Liabilities over 5 years is $7.9 billion, with a median of $7.6 billion recorded in 2022.
• Year-over-year, Total Liabilities retreated 13.59% in 2023 and increased 26.33% in 2026.
• Over 5 years, Total Liabilities stood at $7.3 billion in 2022, then dropped by 13.59% to $6.3 billion in 2023, then rose by 25.13% to $7.9 billion in 2024, then rose by 25.7% to $9.9 billion in 2025, then gained by 1.29% to $10.0 billion in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $10.0 billion in Q2 2026, $9.9 billion in Q1 2026, and $9.9 billion in Q4 2025.